Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

BackgroundWe conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).MethodsWe performed a literature search on PubMed, Cochrane Library, and Clinicaltrials.gov. After screening 677 manuscripts, 13 studies were included. Data was extracted following PRISMA guidelines. Pooled analysis was done using the meta-package by Schwarzer et al. Proportions with 95% confidence intervals (CI) were computed.ResultsWe analyzed 57 patients from 10 clinical trials and 3 case reports. The pooled complete and overall response rates were 49.5% (95% CI 0.18-0.81, I2 =65%) and 65.2% (95% CI 0.36-0.91, I2 =57%). The pooled incidence of cytokine release syndrome, immune-effector cell associated neurotoxicity syndrome, and graft-versus-host disease was estimated as 54.4% (95% CI 0.17-0.90, I2 =77%), 3.9% (95% CI 0.00-0.19, I2 =22%), and 1.6% (95%CI 0.00-0.21, I2 =33%), respectively.ConclusionCAR-T therapy has demonstrated modest efficacy in RR-AML. Major challenges include heterogeneous disease biology, lack of a unique targetable antigen, and immune exhaustion

Luspatercept for beta-thalassemia – A new horizon?

Several treatment options are being explored to reduce the transfusion burden and improve quality of life for patients with beta-thalassemia. One such prospect is the drug luspatercept, which has recently been approved for use in the USA for the treatment of beta-thalassemia. However, socioeconomic factors may act as a barrier to its widespread use

Renal Tubular Acidosis Causing Acute Hypokalemic Paralysis in Systemic Lupus Erythematosus: Sjogren\u27s Syndrome Overlap

Acute hypokalemic paralysis (AHP) is a reversible medical emergency either caused by excessive loss of potassium ions (K+) or increased intracellular shift of K+. Distal renal tubular acidosis (RTA) is an important differential to rule out in patients presenting with AHP. RTA is a constellation of disorders that have been associated with renal damage caused by autoimmune conditions such as systemic lupus erythematosus (SLE) and Sjögren\u27s syndrome (SS). Here we present a case of a 44-year-old woman with a history of SLE in the absence of kidney disease who presented with AHP and was found to have distal RTA and antibodies positive for SS concerning tubulointerstitial nephritis in the setting of SS/SLE overlap syndrome

Adenoid Cystic Cancer

Adenoid cystic carcinoma (ACC) is a rare malignancy arising from the secretory glands, most commonly seen involving the salivary glands. It accounts for approximately 1% of all malignancies of the head and neck region. However, it is the most common tumor of the minor salivary glands and the second most common tumor of the major salivary glands. Overall, it accounts for 10% of all salivary gland tumors. The tumor is typically slow-growing compared to other carcinomas and has a tendency for perineural invasion as well as hematogenous spread to distant organs and is most commonly seen in the elderly. Due to its rarity, limited data is available regarding the predisposing risk factors and the management of patients with advanced disease

Luspatercept for Beta-thalassemia – A New Horizon?

Several treatment options are being explored to reduce the transfusion burden and improve quality of life for patients with beta-thalassemia. One such prospect is the drug luspatercept, which has recently been approved for use in the USA for the treatment of beta-thalassemia. However, socioeconomic factors may act as a barrier to its widespread use

Differentiation Syndrome

Overview of AML Differentiation Syndrome Conclusio